Matching Placebo for Inclisiran
Sponsors
Novartis Pharmaceuticals
Conditions
HypercholesterolemiaPrimary Hypercholesterolemia or Mixed Dyslipidemia
Phase 3
Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.
CompletedNCT05763875
Start: 2023-03-15End: 2024-06-20Updated: 2025-10-16
Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol.
CompletedNCT05888103
Start: 2023-07-11End: 2024-10-24Updated: 2026-01-13